鸭大肠杆菌超广谱β-内酰胺酶的检测及药物敏感性分析

分析鸭大肠杆菌的耐药性与超广谱β-内酰胺酶的关系,为临床相关感染的治疗提供理论依据。采用CLSI推荐的初步筛选试验和表型确证试验方法,检测了临床分离的12株鸭大肠杆菌产超广谱β-内酰胺酶的情况,用微量稀释法测定了环丙沙星等9种抗菌药对其的抗菌活性。临床分离的12株鸭大肠杆菌中,有4株产超广谱β-内酰胺酶,检出率为33%。产超广谱β-内酰胺酶的菌株对多种药物耐药,对氟喹诺酮类药物之间产生交叉耐药,对氟喹诺酮类、氨基糖苷类、头孢菌素类产生多重耐药性,产酶菌的耐药性明显大于非产酶菌。产超广谱β-内酰胺酶是鸭大肠杆菌对抗菌药物产生耐药性的主要机制之一。

The ESBLs Detection of Duck E.coli and Drug Susceptibility Analysis

The relationship between the drug resistance of duck E.coli and extended-spectrum β-lactamases, was analyzed to provide the laboratory theoretical basis for clinical therapy. Preliminary screening test and phenotype confirmatory test recommended by CLSI were used to detect the production of extended-spectrum β-lactamases (ESBLs) in 12 strains of clinical duck E.coli, micro-double dilution was carried out to determine the antibacterial activity of 9 antimicrobials (Ciprofloxacin). The results indicated that 4 of 12 isolates product ESBLs, accounting for 33%. The strains with ESBLs-producing had resistances to many kinds of antimicrobials,had crossing resistances to fluoroquinolones (FQNs) and had multidrug resistances to fluoroquinolones (FQNs), aminoglycosides and cephalosporins (CEPs). The resistance of ESBLs-producing strains was higher than non-ESBLs-producing strains significantly. ESBLs-producing was one of the major mechanism that duck E.coli formed resistances.